You may not be able to teach old dogs new tricks, but drug companies can certainly try to get old drugs approved for new indications.Baxter (NYSE: BAX) is partnering with the Alzheimer’s Disease Cooperative Study Group to see whether its Gammagard Liquid can be used to treat the dreaded neurodegenerative disorder. The company announced that it plans to proceed with a phase 3 clinical trial, after interim results of an ongoing 24-person phase 2 trial looked promising. The full results from that trial should be available later this year, and the phase 3 clinical trial should begin enrolling patients next year.
